Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456169 | 0.75 | CCR1 (0.37) | — | |
| SCHEMBL14334477 | 0.75 | KDM4E (0.53) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL11082771 | 0.74 | GAA (0.47) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL10614056 | 0.74 | KDM4E (0.45) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2052133 | 0.73 | — | — | |
| SCHEMBL2039964 | 0.73 | IDO1 (0.38) | — | |
| SCHEMBL15331872 | 0.73 | NPC1 (0.41) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15331385 | 0.72 | MAPK13 (0.34) | — | |
| SCHEMBL15329607 | 0.72 | HSD17B1 (0.34) | KDM4EALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL15330775 | 0.72 | MAPT (0.36) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2513105-B1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-05-14 | — | — | EP | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
| EP-2513105-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072696-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | KDM4E 424/4885HPGD 1059/4885ALDH1A1 54/4885 |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | KDM4E 424/4885HPGD 1059/4885ALDH1A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.